New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:52 EDTORAN, SNY, SLBWestern companies may seek return to Iran as sanctions ease, WSJ says
Temporary sanctions relief hasn't yet translated into an economic turnaround in Iran, but a steady flow of executives in recent weeks signals that some companies that previously did business there, such as Schlumberger (SLB), Sanofi (SNY), and Orange (ORAN), may be interested in exploring a return, according to The Wall Street Journal. Reference Link
News For ORAN;SNY;SLB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 17, 2014
08:48 EDTSLBSchlumberger sees 5c-7c EPS growth in Q4 vs. Q3
Sees Libya and Russia continuing to have an affect on earnings during Q4. Libya's Q3 activity was down 50% year over year.
08:47 EDTSLBSchlumberger sees international earnings growth in FY15
Schlumberger management stated that Russian sanctions has a 2c per share impact on Q3. The company will re-size Libyan resources and oil rigs in Iraq are slowly going back into operation. Management stated that the company did several deals for artificial lift work. The company's outlook for global GDP growth softened slightly. The company sees Brent oil prices recovering and stabilizing. Management stated that global economic recover is remains intact. The company stated that global spare oil capacity is not increasing. Management stated that 10 new deep-water rigs are scheduled for delivery in Q4. The company sees a 6% decline in deep-water drilling, primarily driven by Brazil. The company sees FY15 deep-water drilling flat. The company sees FY 14 exploration spending down 4%-5%. Comments made during Q3 earnings conference call.
October 16, 2014
16:10 EDTSLBSchlumberger says world economy 'slow but steady recovery' intact
Subscribe for More Information
16:09 EDTSLBSchlumberger reports Q3 EPS $1.49, consensus $1.46
Reports Q3 revenue $12.6B, consensus $12.64B. Schlumberger CEO Paal Kibsgaard said, “Strong activity in North America and robust growth in International Areas, led by Latin America and supported by Europe/Africa/CIS in spite of international sanctions in Russia, drove third-quarter results to a new record high. At the same time, Middle East & Asia proved highly resilient in the face of significant headwinds in Northern Iraq. All Areas and all Groups recorded growth, backed by new technology penetration and strong operational execution."
15:26 EDTSLBNotable companies reporting after market close
Subscribe for More Information
11:26 EDTORANOrange, Deutsche Telekom talks on potential sale of EE revived, Bloomberg says
Subscribe for More Information
11:20 EDTORANOrange, Deutsche Telekom talks on potential sale of EE revived, Bloomberg says
Subscribe for More Information
08:19 EDTSNYSanofi Pasteur, Immune Design enter collaboration HSV therapy
Immune Design (IMDZ) announced that it has entered into a broad collaboration for the development of a herpes simplex virus, or HSV, immune therapy with Sanofi Pasteur, the vaccines division of Sanofi (SNY). Sanofi Pasteur and Immune Design will each contribute product candidates to the collaboration: Sanofi Pasteur will contribute HSV-529, a clinical-stage replication-defective HSV vaccine product candidate, and Immune Design will contribute G103, its preclinical trivalent vaccine product candidate. The collaboration will explore the potential of various combinations of agents, including leveraging Immune Design's GLAASTM platform, with the goal to select the best potential immune therapy for patients. The two companies will develop the products jointly through Phase 2 clinical trials, at which point Sanofi Pasteur intends to continue development of the most promising candidate and be responsible for commercialization. Sanofi Pasteur will bear the costs of all preclinical and clinical development, with Immune Design providing a specific formulation of GLA from the GLAAS platform at its cost through Phase 2 studies. Immune Design will be eligible to receive future milestone and royalty payments on any product developed from the collaboration; other financial terms of the agreement have not been disclosed.
October 15, 2014
11:39 EDTSLBOil services companies rebound after positive notes from analysts
Subscribe for More Information
10:02 EDTSLBOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Atwood Oceanics (ATW) initiated with a Buy at ISI Group... Baker Hughes (BHI) initiated with a Buy at Citigroup... Basic Energy (BAS) initiated with a Buy at ISI Group... C&J Energy (CJES) initiated with a Buy at ISI Group... CARBO Ceramics (CRR) initiated with a Hold at ISI Group... CHC Group (HELI) initiated with a Buy at ISI Group... Cameron (CAM) initiated with a Buy at ISI Group... Chart Industries (GTLS) initiated with a Buy at ISI Group... Core Laboratories (CLB) initiated with a Buy at ISI Group... Diamond Offshore (DO) initiated with a Sell at ISI Group... Dresser-Rand (DRC) initiated with a Sell at ISI Group... Dril-Quip (DRQ) initiated with a Buy at ISI Group... Ensco (ESV) initiated with a Buy at ISI Group... FIS (FIS) initiated with a Market Perform at BMO Capital... FMC Technologies (FTI) initiated with a Buy at ISI Group... GoPro (GPRO) initiated with a Sector Perform at Pacific Crest... Halliburton (HAL) initiated with a Buy at ISI Group... Helmerich & Payne (HP) initiated with a Neutral at Citigroup... Hercules Offshore (HERO) initiated with a Sell at ISI Group... Key Energy (KEG) initiated with a Buy at ISI Group... Maxwell (MXWL) reinstated with a Buy at Canaccord... Nabors Industries (NBR) initiated with a Buy at ISI Group... Noble Corp. (NE) initiated with a Buy at ISI Group... Oceaneering (OII) initiated with a Buy at ISI Group... Paragon Offshore (PGN) initiated with a Buy at ISI Group... Parker Drilling (PKD) initiated with a Buy at ISI Group... Patterson-UTI (PTEN) initiated with a Buy at Citigroup... Peabody (BTU) initiated with an Underperform at Imperial Capital... RPC, Inc. (RES) initiated with a Buy at Citigroup... Receptos (RCPT) initiated with a Buy at Goldman... Rowan Companies (RDC) initiated with a Buy at ISI Group... Schlumberger (SLB) initiated with a Buy at ISI Group... Sensata (ST) resumed with a Buy at Citigroup... Tidewater (TDW) initiated with a Hold at ISI Group... Transocean (RIG) initiated with a Sell at ISI Group... Weatherford (WFT) initiated with a Buy at ISI Group.
10:02 EDTSNYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:29 EDTSNYSelecta, JDRF, Sanofi extend collaboration for SVP immunotherapy
Subscribe for More Information
07:11 EDTSLBSchlumberger initiated with a Buy at ISI Group
Subscribe for More Information
06:32 EDTSLBCiti rolls out Oil Services coverage, recommends two pair trades
Subscribe for More Information
06:11 EDTSLBSchlumberger initiated with a Neutral at Citigroup
Target $92.
05:26 EDTSNYSanofi upgraded to Outperform from Neutral at Credit Suisse
October 14, 2014
11:23 EDTSNYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
09:00 EDTSNYSanofi rotavirus vaccine enters Phase III trials in India
Subscribe for More Information
08:08 EDTSNYRegulus Therapeutics to present new preclinical data on multiple programs
Regulus Therapeutics (RGLS) announced that it will present new preclinical data on multiple programs and an overview of its clinical portfolio at the 10th Annual Oligonucleotide Therapeutics Society meeting being held October 12-October 15 at the Hilton San Diego Resort and Spa. In a poster titled "Anti-Diabetic Activity of miR-103/107 Anti-miRs", Regulus scientists will present preclinical data further demonstrating the potential benefit of a microRNA therapeutic for the treatment of metabolic disorders. In a poster titled "Inhibition of miR-21 with RG-012 Improves Renal Function and Survival in Multiple Strains of Col4A3 Deficient Mice", Regulus scientists, in collaboration with its strategic alliance partner Sanofi (SNY), will present new preclinical data demonstrating that weekly subcutaneous delivery of RG-012 has shown to provide both glomerular and tubule protection in the kidneys of Col4A3 deficient mice in an Alport syndrome model.
October 13, 2014
08:02 EDTSLBOneSubsea awarded $270M contract for Pemex Lakach Deepwater Development
OneSubsea, a Cameron (CAM) and Schlumberger (SLB) company, has been awarded a subsea production systems contract totaling more than $270M for the Lakach deepwater project offshore Mexico. This is the first deepwater subsea field to be developed by Pemex. The scope of supply for the seven well system includes subsea production equipment and tooling. OneSubsea will also provide installation and commissioning services. Deliveries are expected to begin in June 2016.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use